Charles River initially unveiled a plan to adopt new alternative methods (NAMs), like computer models and human organoids, in ...

Alis Biosciences has made a pitch to the hundreds of biotechs that are valued at less than the cash they have in the bank.

The U.S. government has pulled the rug out from under Pluri Biotech’s PLX-R18 cell therapy. | The U.S. government has pulled ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

VelaVigo Bio has landed its second deal in six months, offloading ex-China rights to a bispecific to Ollin Biosciences for up ...

Just a few weeks after closing a $155 million series B, RNA editing biotech AIRNA is bringing an experienced gene therapy ...

After mass layoffs, the FDA has started missing certain deadlines, pushing one biopharma to delay a phase 3 trial and ...

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of ...

Precision Neuroscience has obtained an FDA clearance for a crucial piece of its plans for a full brain-computer interface ...

The material is employed in a range of Edwards’ surgical and transcatheter valves, including versions of the Inspiris, Mitris ...

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

Novartis has terminated a phase 2 trial evaluating an investigational ADAMTS-5 inhibitor for patients with osteoarthritis ...